no side effects from semaglutide In four recent placebo-controlled clinical trials, dysesthesia, an unpleasant sensation that's perceived on or under the skin, was reported as a effect of the GLP-1 agonist in 5-23% of recipients Harvard and CDC study: Serious

When given orally, semaglutide is dosed differently as absorption and delivery are different from injectable semaglutide (more on that below)

Over time, pharmacological engineering enabled: Short-acting injectables (e.g., exenatide) Long-acting once-weekly injectables (liraglutide, semaglutide) Multi-target incretin therapies (tirzepatide) Oral peptide formulations and now oral small molecules The most recent breakthrough is the development of orally available GLP-1 receptor agonists, including: Orforglipron (Lilly) Elecoglipron (AstraZeneca) These compounds eliminate the need for injection and could dramatically expand accessibility and adherence in obesity and diabetes populations

BBB rating: F

10.1161/JAHA.118.009700 109

Zinc and copper interactions in human nutrition